Navigation Links
Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine

BROOMFIELD, Colo., Sept. 21, 2011 /PRNewswire/ -- Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).

While the precise cause of migraines is not fully understood, changes in vascular tone and inflammatory processes appear to be key contributing factors.  Prostaglandins are naturally existing molecules that are integral components of both vascular and inflammatory reactions in the central and peripheral nervous systems.   There is evidence to demonstrate that prostaglandin E2 (PGE2) binding to the EP4 receptor causes dilation of small blood vessels in the brain, while leaving coronary and pulmonary arteries unaffected, and can stimulate a variety of inflammatory mechanisms.  AP-1531 is a potent and selective EP4 receptor antagonist that specifically targets PGE2-EP4 binding which may treat migraines. AP-1531 has shown promising results  in several disease models of migraine and acute pain and inflammation.  

"We are extremely pleased with the data from six Phase I studies on AP-1531 and are confident this approach will yield positive results as we initiate a Phase 2 study in migraine patients in 2012," said Steve Orndorff, President and CEO of Ariel Pharmaceuticals.  "Given that the current standard of care for moderate to severe migraines can take up to 90 minutes to provide relief and works temporarily or not at all in many patients, in addition to having potentially serious side effects, we're committed to developing a safer and more efficacious alternative that will provide better quality care to patients.  We believe AP-1531 will validate our business model of in-licensing clinic-ready drugs in acute care clinical indications to expeditiously build value for our shareholders."

Episodic migraine headaches affect more than 10% of the world population and are among the top four disabling neurological conditions.  Migraines account for an estimated 30 million days of lost productivity at a cost of up to $17 billion per year in the U.S.  Almost half of migraine patients suffer severe pain and require bed rest.  Currently, the most common migraine therapies are non-steroidal anti-inflammatory drugs (NSAIDs) and triptans (5-HTIB/1D agonists).  Shortcomings of these drugs include failure to work in a significant percentage of patients, slow speed of activity, recurrence of pain and potentially debilitating side effects, including cardiovascular and gastrointestinal toxicity.

About Ariel Pharmaceuticals, Inc.

Ariel Pharmaceuticals, Inc. is a private, specialty pharmaceutical company focused on the development and commercialization of drugs that improve quality of life for patients with acute neurological disorders and trauma.  Ariel is developing three drugs intended to meet unmet medical needs in migraine, hemorrhagic shock and post-operative cognitive decline.  The company's business strategy is based on in-licensing clinic-ready drugs in acute care clinical indications that have well-defined efficacy endpoints and where there is little to no competition in order to enable Ariel to rapidly build shareholder value.  For more information, please visit:

Ariel Pharmaceuticals, Inc.
Steve Orndorff, PhD
President & CEO

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach
Jason Rando

SOURCE Ariel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariel Ways GovBuys Awarded VA Contract
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate the ... 57 th American Society of Hematology (ASH) Annual ... myelomas as well as supportive care, including key findings ... personalized cell therapies. The ASH Annual Meeting will be ... . Novartis Oncology . "We will be ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, Ltd., ... and developing innovative therapies for ear, nose, and throat ... A. Katkin as chairman of the company,s board ... executive officer for OticPharma, Ltd.  "Keith brings a wealth ... will be able to share this experience and provide ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) ... for the Nutraceutical Specialties products into oral solid dosage in the over the ... “We are pleased to announce our expanded distribution agreement with ASI.” said Steve ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is ... "My last baby had high blood pressure due to loud noises," she said, "so ... babies from noise pollution as well as radio waves and microwaves." , The baby ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The ... and technical experience available within DataTrade to extend the services currently provided by ...
Breaking Medicine News(10 mins):